630nm激光联合血卟啉衍生物治疗晚期支气管肺癌的近期临床疗效分析

Short-term clinical efficacy of 630 nm laser combined with hematoporphyrin derivatives in treatment of advanced bronchial lung cancer

目的探讨630 nm激光联合血卟啉衍生物治疗晚期支气管肺癌的近期临床疗效及安全性。方法选择青岛大学附属医院2019年3月至2023年9月经病理确诊的43例晚期支气管肺癌患者,行支气管肺癌介入治疗后,联合630 nm激光和血卟啉衍生物及化疗、免疫治疗。随访患者基本临床特征及治疗后的不良反应,治疗后1个月复查胸部CT及支气管镜检查。结果胸部CT显示治疗后气管或支气管内肿瘤体积较术前明显缩小,改善通气。支气管镜检查显示,治疗后肿瘤体积减小,甚至消失。治疗1个月后按时复查胸部CT及支气管镜检查的患者为31例(72.09%),31例患者的总有效率70.97%。43例患者均未出现严重并发症,但3例患者出现常见并发症。结论630 nm激光联合血卟啉衍生物治疗晚期支气管肺癌近期临床疗效明显,能改善气道狭窄,缓解呼吸困难、咳嗽等症状,安全性好,值得在临床推广应用。

To analyze the short-term clinical efficacy and safety of 630 nm laser combined with hematoporphyrin derivatives in the treatment of advanced bronchial lung cancer.Methods A total of 43 patients with pathologically diagnosed bronchial lung cancer who underwent interventional tumor reduction combined with treatment with 630 nm laser and hematoporphyrin derivatives,chemotherapy,and immunotherapy were selected at the Affiliated Hospital of Qingdao University from March 2019 to September 2023.The basic clinical features and adverse reactions after treatment were recorded,and chest CT and bronchoscopy were reviewed 1 month after treatment.Results Chest CT showed that the tumor volume in the trachea or bronchus was significantly reduced after treatment,and ventilation was improved.Bronchoscopy showed that the tumor volume decreased or even disappeared after treatment.After 1 month of treatment,31 patients(72.09%)were re-examined by chest CT and bronchoscopy,and the total effective rate was 70.97%.None of the 43 patients had serious complications,but 3 patients had common complications.Conclusion 630 nm laser combined with hematoporphyrin derivatives has obvious clinical efficacy in the treatment of advanced bronchial lung cancer,and it can improve airway stenosis and relieve dyspnea,cough,and other symptoms with a favorable safety profile.